Total Payments
$53,504
2024 Payments
$13,618
Companies
8
Transactions
33
Payment Breakdown by Category
Consulting$51,284 (95.9%)
Travel$1,594 (3.0%)
Food & Beverage$625.89 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $51,284 | 14 | 95.9% |
| Travel and Lodging | $1,594 | 7 | 3.0% |
| Food and Beverage | $625.89 | 12 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29,588 | 8 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $12,083 | 10 | $0 (2020) |
| Alkermes, Inc. | $8,606 | 9 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $3,023 | 1 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $96.71 | 1 | $0 (2019) |
| Lundbeck LLC | $51.25 | 1 | $0 (2022) |
| Boston Scientific Corporation | $43.69 | 2 | $0 (2023) |
| Allergan Inc. | $13.25 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,618 | 3 | Boehringer Ingelheim Pharmaceuticals, Inc. ($13,618) |
| 2023 | $7,299 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,255) |
| 2022 | $6,981 | 3 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,930) |
| 2021 | $4,808 | 2 | Merck Sharp & Dohme Corporation ($3,023) |
| 2020 | $2,646 | 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($2,646) |
| 2019 | $12,197 | 11 | Alkermes, Inc. ($7,583) |
| 2018 | $5,943 | 8 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($4,920) |
| 2017 | $13.25 | 1 | Allergan Inc. ($13.25) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,467.50 | General |
| 11/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 02/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,650.00 | General |
| 12/20/2023 | Boston Scientific Corporation | SpyGlass Discover (Device) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: SpyGlass Discover_ENDO | ||||||
| 09/20/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,505.00 | General |
| 06/27/2023 | Boston Scientific Corporation | SpyGlass (Device) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: SpyGlass_ENDO | ||||||
| 01/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| 12/20/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| 10/18/2022 | Lundbeck LLC | — | Food and Beverage | Cash or cash equivalent | $51.25 | General |
| 09/27/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,250.00 | General |
| 12/10/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $3,022.50 | General |
| 11/30/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,785.00 | General |
| 12/01/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,646.00 | General |
| 09/20/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $575.60 | General |
| 09/20/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $6.00 | General |
| 09/20/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $6.00 | General |
| 09/20/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | Cash or cash equivalent | $4.53 | General |
| 07/30/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,608.00 | General |
| 07/30/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $192.66 | General |
| 06/20/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $124.36 | General |
| 05/19/2019 | Sunovion Pharmaceuticals Inc. | — | Food and Beverage | Cash or cash equivalent | $96.71 | General |
| 01/14/2019 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Consulting Fee | Cash or cash equivalent | $7,500.00 | General |
| Category: CNS | ||||||
| 01/14/2019 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Travel and Lodging | In-kind items and services | $43.08 | General |
| Category: CNS | ||||||
| 01/14/2019 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Travel and Lodging | In-kind items and services | $39.98 | General |
| Category: CNS | ||||||
| 11/27/2018 | Alkermes, Inc. | Aristada 441 mg (Drug), Aristada 662mg, Aristada 882mg | Food and Beverage | In-kind items and services | $53.93 | General |
| Category: CNS | ||||||
About Dr. Joseph Parks, M.D
Dr. Joseph Parks, M.D is a Psychiatry healthcare provider based in Columbia, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1003898495.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Parks, M.D has received a total of $53,504 in payments from pharmaceutical and medical device companies, with $13,618 received in 2024. These payments were reported across 33 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($51,284).
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry, Psychiatry
- Location Columbia, MO
- Active Since 11/19/2005
- Last Updated 01/02/2025
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1003898495
Products in Payments
- ARISTADA (Drug) $7,583
- Aristada 441 mg (Drug) $897.90
- Vivitrol 380 mg (Drug) $124.88
- SpyGlass (Device) $23.30
- SpyGlass Discover (Device) $20.39
- VRAYLAR (Drug) $13.25
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Columbia
Dr. Meera Narasimhan, M.d, M.D
Psychiatry — Payments: $57,045
Psychiatry $57,045
Agara Reddy, Md, MD
Psychiatry — Payments: $15,068
Psychiatry $15,068
Deborah Leverette, Md Mph, MD MPH
Psychiatry — Payments: $12,750
Psychiatry $12,750
Gariane Gunter, M.d, M.D
Psychiatry — Payments: $11,480
Psychiatry $11,480
Dr. Nioaka Campbell, M.d, M.D
Psychiatry — Payments: $10,898
Psychiatry $10,898
Dr. Daniel Storch, Md, MD
Psychiatry — Payments: $9,024
Psychiatry $9,024